Psoriasis Clinical Trial
Official title:
Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life
Objective of the study is to create and validate Chronic Quality of Life (CQOL) index that
explores habits, career paths and other life choices psoriasis patients make as a result of
coping with their disease that may not be impacted by therapy implemented at a given point
in time.
- The investigators think this data will show that patients who were diagnosed at a young
age will have worse chronic quality of life.
As a visible disease, psoriasis can be embarrassing and psychosocially stressful in addition
to physically uncomfortable. Patients' lives are affected in physical, psychological,
social, sexual and occupational aspects. These burdens may cause patients to assume
maladaptive habits and coping mechanisms, leading to a downward spiral in functioning within
society, prohibiting patients from achieving their highest potential quality of life.
The investigators' study goal is to create and validate Chronic Quality of Life (CQOL) index
that explores habits, career paths and other life choices psoriasis patients make as a
result of coping with their disease that may not be impacted by therapy implemented at a
given point in time. In creating this questionnaire and validating it the investigators will
collect preliminary data. The investigators think this data will show that patients who were
diagnosed at a young age will have worse chronic quality of life. In the long run, the
investigators will use the CQOL index in studies in which patients are treated for psoriasis
to determine which treatments can change a psoriasis patient's chronic quality of life. This
information will be used to create guidelines for treatment focused on achieving a patient's
optimal quality of life.
Another aspect that the investigators would like to look at is the skin carotenoid levels in
the psoriasis population. Previous studies showed that psoriasis patients had lower levels
of skin carotenoids when compared to healthy volunteers. This observation was not
statistically significant perhaps due to a small sample size (21 subjects in the psoriasis
group and 35 subjects in the control group). Skin carotenoid levels measurement is optional
for study subjects.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |